ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Development of De Novo Aortic Insufficiency in Patients With HeartMate 3

Friday, August 19, 2022

Submitted by

Mary Hammon

Source

Source Name: Annals of Thoracic Surgery

Source URL: https://doi.org/10.1016/j.athoracsur.2021.08.074

Author(s)

Alyyah Malick, BA, Yuming Ning, PhD, Paul A. Kurlansky, MD, Andrew Melehy, MD, Melana Yuzefpolskaya, MD, Paolo C. Colombo, MD, Gabriel Sayer, MD, Nir Uriel, MD, MSc, Yoshifumi Naka, MD, PhD, and Koji Takeda, MD, PhD

This study compared the development of de novo aortic insufficiency (AI), the a common adverse event after continuous-flow left ventricular assist device (LVAD) placement, between HeartMate 3 (Abbott) and HeartMate II LVAD recipients. Researchers ultimately concluded there is no significant difference in severity of AI between HeartMate II and HeartMate 3 patients.